You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePregnenolone
Accession NumberDB02789  (EXPT02608)
TypeSmall Molecule
GroupsExperimental
DescriptionA 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS. [PubChem]
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII73R90F7MQ8
CAS numberNot Available
WeightAverage: 316.4776
Monoisotopic: 316.240230268
Chemical FormulaC21H32O2
InChI KeyORNBQBCIOKFOEO-QGVNFLHTSA-N
InChI
InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4,15-19,23H,5-12H2,1-3H3/t15-,16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
1-[(1S,2R,5S,10S,11S,14S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-7-en-14-yl]ethan-1-one
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Sulfotransferase family cytosolic 2B member 1ProteinunknownNot AvailableHumanO00204 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
SubstrateEnzymesProduct
Pregnenolone
Not Available
17-Hydroxypregnenolone sulfateDetails
Pregnenolone
Not Available
Pregnenolone sulfateDetails
Pregnenolone
Not Available
3beta-Hydroxypregn-5-en-20-one sulfateDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pregnenolone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Pregnenolone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pregnenolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pregnenolone.Approved
AldesleukinPregnenolone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Pregnenolone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Pregnenolone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Pregnenolone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Pregnenolone.Approved
AmiodaroneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BPregnenolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pregnenolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pregnenolone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Pregnenolone.Approved, Investigational
AprepitantThe serum concentration of Pregnenolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Pregnenolone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Pregnenolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pregnenolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pregnenolone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pregnenolone.Approved, Investigational
BazedoxifeneThe serum concentration of Pregnenolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazidePregnenolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pregnenolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Pregnenolone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Pregnenolone.Investigational
Bismuth SubcitrateThe bioavailability of Pregnenolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Pregnenolone can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pregnenolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pregnenolone.Investigational
BumetanidePregnenolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Pregnenolone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Pregnenolone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Pregnenolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pregnenolone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pregnenolone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Pregnenolone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pregnenolone.Approved, Investigational
CeritinibPregnenolone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pregnenolone.Approved, Vet Approved
ChlorothiazidePregnenolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Pregnenolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidonePregnenolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Pregnenolone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pregnenolone.Approved
CobicistatThe serum concentration of Pregnenolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Pregnenolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Pregnenolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Pregnenolone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Pregnenolone.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Pregnenolone.Investigational
DarunavirThe serum concentration of Pregnenolone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Pregnenolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pregnenolone.Approved, Vet Approved
DienestrolThe serum concentration of Pregnenolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Pregnenolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pregnenolone.Approved
DihydrotestosteronePregnenolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pregnenolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pregnenolone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Pregnenolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Pregnenolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Pregnenolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pregnenolone.Approved
EstradiolThe serum concentration of Pregnenolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Pregnenolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Pregnenolone can be increased when it is combined with Estrone.Approved
Etacrynic acidPregnenolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pregnenolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Pregnenolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pregnenolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pregnenolone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pregnenolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pregnenolone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Pregnenolone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pregnenolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pregnenolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pregnenolone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pregnenolone.Vet Approved
FluoxymesteronePregnenolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pregnenolone.Approved, Investigational
FosaprepitantThe serum concentration of Pregnenolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Pregnenolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemidePregnenolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Pregnenolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Pregnenolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Pregnenolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Pregnenolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Pregnenolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pregnenolone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Pregnenolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pregnenolone.Approved, Investigational
HydrochlorothiazidePregnenolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazidePregnenolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pregnenolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pregnenolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pregnenolone.Approved
IdelalisibThe serum concentration of Pregnenolone can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Pregnenolone.Approved
IndapamidePregnenolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Pregnenolone can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pregnenolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pregnenolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Pregnenolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pregnenolone.Withdrawn
ItraconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pregnenolone.Experimental
KetoconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pregnenolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pregnenolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pregnenolone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pregnenolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Pregnenolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pregnenolone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pregnenolone.Approved
LumacaftorThe serum concentration of Pregnenolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pregnenolone.Approved, Investigational
MagaldrateThe bioavailability of Pregnenolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Pregnenolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Pregnenolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Pregnenolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pregnenolone.Approved
Magnesium TrisilicateThe bioavailability of Pregnenolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pregnenolone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pregnenolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pregnenolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pregnenolone.Approved
MestranolThe serum concentration of Pregnenolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pregnenolone.Withdrawn
MethallenestrilThe serum concentration of Pregnenolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazidePregnenolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteronePregnenolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazonePregnenolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Pregnenolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Minaprine.Approved
MitotaneThe serum concentration of Pregnenolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Pregnenolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pregnenolone.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pregnenolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pregnenolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pregnenolone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pregnenolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pregnenolone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Pregnenolone.Investigational
NefazodoneThe serum concentration of Pregnenolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pregnenolone.Approved
NevirapineThe serum concentration of Pregnenolone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pregnenolone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pregnenolone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pregnenolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnenolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pregnenolone.Vet Approved
OxandrolonePregnenolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pregnenolone.Approved
OxymetholonePregnenolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pregnenolone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pregnenolone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Pregnenolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Pregnenolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Pregnenolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pregnenolone.Approved, Vet Approved
PhenytoinThe serum concentration of Pregnenolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pregnenolone.Approved, Investigational
PiretanidePregnenolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pregnenolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pregnenolone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Pregnenolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazidePregnenolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Pregnenolone can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Pregnenolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pregnenolone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pregnenolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Pregnenolone can be increased when it is combined with Quinestrol.Approved
QuinethazonePregnenolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Pregnenolone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pregnenolone.Experimental, Investigational
RifabutinThe serum concentration of Pregnenolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Pregnenolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pregnenolone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Pregnenolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pregnenolone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Pregnenolone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pregnenolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pregnenolone.Approved
SaquinavirThe serum concentration of Pregnenolone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Pregnenolone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pregnenolone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Pregnenolone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Pregnenolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pregnenolone.Investigational
St. John's WortThe serum concentration of Pregnenolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololPregnenolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pregnenolone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pregnenolone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pregnenolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Pregnenolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Pregnenolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Pregnenolone.Approved
TelithromycinThe serum concentration of Pregnenolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pregnenolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pregnenolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Pregnenolone.Approved
TestosteronePregnenolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Pregnenolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pregnenolone.Approved
TiboloneThe serum concentration of Pregnenolone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pregnenolone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pregnenolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pregnenolone.Approved
TorasemidePregnenolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pregnenolone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Trichlorfon.Vet Approved
TrichlormethiazidePregnenolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pregnenolone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pregnenolone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Pregnenolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinPregnenolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pregnenolone.Approved
ZeranolThe serum concentration of Pregnenolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pregnenolone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pregnenolone.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Alexander James Bridges, “Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone.” U.S. Patent US20080171728, issued July 17, 2008.

US20080171728
General References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9671
Caco-2 permeable+0.8568
P-glycoprotein substrateSubstrate0.6106
P-glycoprotein inhibitor IInhibitor0.6721
P-glycoprotein inhibitor IINon-inhibitor0.7531
Renal organic cation transporterNon-inhibitor0.7825
CYP450 2C9 substrateNon-substrate0.8333
CYP450 2D6 substrateNon-substrate0.8417
CYP450 3A4 substrateSubstrate0.7594
CYP450 1A2 substrateNon-inhibitor0.9179
CYP450 2C9 inhibitorNon-inhibitor0.9333
CYP450 2D6 inhibitorNon-inhibitor0.9558
CYP450 2C19 inhibitorNon-inhibitor0.9023
CYP450 3A4 inhibitorNon-inhibitor0.8332
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9076
Ames testNon AMES toxic0.9439
CarcinogenicityNon-carcinogens0.9346
BiodegradationNot ready biodegradable0.9379
Rat acute toxicity1.9852 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8779
hERG inhibition (predictor II)Non-inhibitor0.7239
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0136 mg/mLALOGPS
logP4.06ALOGPS
logP3.58ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)18.2ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity93.76 m3·mol-1ChemAxon
Polarizability38.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-0fic-5910000000-4b4de0891180a420522aView in MoNA
MSMass Spectrum (Electron Ionization)splash10-052f-6920000000-2b11c86505b10fe4485fView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 3-beta-hydroxysteroid
  • 3-beta-hydroxy-delta-5-steroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-hydroxysteroid
  • 3-hydroxy-delta-5-steroid
  • Delta-5-steroid
  • Cyclic alcohol
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid sulfotransferase activity
Specific Function:
Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs and xenobiotic compounds. Sulfonation increases the water solubility of most compounds, and therefore their renal excretion, but it can also result in bioactivation to form active metabolites. Sulfates hydroxysteroids like DHEA. I...
Gene Name:
SULT2B1
Uniprot ID:
O00204
Molecular Weight:
41307.32 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-dependent organic anion transmembrane transporter activity
Specific Function:
Transports sulfoconjugated steroid hormones, as well as taurolithocholic acid-3-sulfate and sulfoconjugated pyrenes in a sodium-dependent manner.
Gene Name:
SLC10A6
Uniprot ID:
Q3KNW5
Molecular Weight:
41258.24 Da
References
  1. Geyer J, Doring B, Meerkamp K, Ugele B, Bakhiya N, Fernandes CF, Godoy JR, Glatt H, Petzinger E: Cloning and functional characterization of human sodium-dependent organic anion transporter (SLC10A6). J Biol Chem. 2007 Jul 6;282(27):19728-41. Epub 2007 May 9. [PubMed:17491011 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23